Adaptive Biotechnologies (NASDAQ:ADPT) Announces Earnings Results, Beats Expectations By $0.12 EPS

Adaptive Biotechnologies (NASDAQ:ADPT) released its earnings results on Wednesday. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.12, FiscalAI reports. The company had revenue of $83.90 million during the quarter, compared to analysts’ expectations of $71.57 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. Adaptive Biotechnologies’s revenue for the quarter was down 10.7% on a year-over-year basis. During the same period last year, the business earned $0.06 EPS.

Here are the key takeaways from Adaptive Biotechnologies’ conference call:

• Adaptive reported Q3 revenue of $83.9 million, up 39%, and MRD revenue growth of 44% excluding prior-year milestones. It generated $14.3 million in adjusted EBITDA and $8 million in free cash flow, and raised its 2026 MRD revenue guidance to $276 million–$286 million.
• Clinical testing volume grew 46% year over year to nearly 40,000 clonoSEQ tests, with growth across reimbursed indications. Blood-based and community testing also expanded; management said updated myeloma guidelines and a new definition of cure could further support adoption, though those benefits remain prospective.
• MRD pharma sequencing revenue grew 55% year over year excluding milestones, while the study portfolio reached 191 active studies and backlog rose 34% to about $270 million. Management expects approximately 25% full-year pharma sequencing growth, but noted that quarterly revenue and milestone timing can be lumpy.
• More frequent Medicare testing beyond the existing four-test episode bundle pressured realized ASP, particularly in multiple myeloma. Adaptive has submitted for an additional maintenance-testing bundle and is in discussions with MolDX, but the timing and terms of any expanded coverage are uncertain; the company also said it does not expect full-year GAAP net income or positive EPS.
• Adaptive said it remains on track to announce a path forward for separating its Immune Medicine business by year end. The segment recognized a Pfizer milestone after delivering rheumatoid arthritis data, but management did not provide details on the separation outcome.

Adaptive Biotechnologies Trading Up 3.5%

Shares of Adaptive Biotechnologies stock traded up $0.91 on Wednesday, reaching $26.71. 2,326,040 shares of the stock were exchanged, compared to its average volume of 1,999,355. The company has a current ratio of 4.79, a quick ratio of 4.68 and a debt-to-equity ratio of 2.22. Adaptive Biotechnologies has a twelve month low of $12.00 and a twelve month high of $30.74. The business has a 50 day moving average price of $26.37 and a two-hundred day moving average price of $19.76.

Insider Buying and Selling

In other Adaptive Biotechnologies news, insider Francis Lo sold 115,406 shares of Adaptive Biotechnologies stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $28.06, for a total transaction of $3,238,292.36. Following the completion of the sale, the insider directly owned 220,867 shares in the company, valued at approximately $6,197,528.02. The trade was a 34.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad Robins sold 321,324 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $25.08, for a total transaction of $8,058,805.92. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at $54,687,391.44. This trade represents a 12.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 1,050,763 shares of company stock worth $26,806,633 in the last quarter. 5.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ADPT. Morgan Stanley raised their price target on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Guggenheim lifted their price objective on shares of Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. TD Cowen boosted their price objective on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. The Goldman Sachs Group assumed coverage on shares of Adaptive Biotechnologies in a report on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.06.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.